Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion, however, causes secondary damage. An emerging approach for treatment of ischemia-reperfusion (IR) injury involves the delivery of therapeutic nanoparticles to the myocardium to promote cell survival and constructively influence scar formation and myocardial remodeling. The aim of this study was to provide detailed understanding of the in vivo accumulation and distribution kinetics of lipid-based nanoparticles (micelles and liposomes) in a mouse model of acute and chronic IR injury. Both micelles and liposomes contained paramagnetic and fluorescent lipids and could therefore be visualized with magnetic resonance imaging (MRI) and confocal laser scanning micro...
Myocardial ischemia-reperfusion injury is a kind of pathologic physiology, clinical refers to, when ...
Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modifi...
Background: Atherosclerosis is a chronic inflammatory disease of the large arteries and a leading ca...
Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion, however, causes ...
Adverse cardiac remodeling after myocardial infarction ultimately causes heart failure. To stimulate...
Ischemic heart disease is the leading cause of death worldwide. Occlusion of a coronary artery resul...
Myocardial infarction is the leading cause of death world-wide. It is characterized by cardiomyocyte...
Myocardial infarction (MI) affects nearly 800,000 people every year in the United States. As it stan...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Atherosclerosis is a leading cause of worldwide morbidity and mortality whose management could benef...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Ischemic cardiac disease (ICD) is a cardiovascular disease with high morbidity and mortality. In thi...
Myocardial ischemia-reperfusion injury is a kind of pathologic physiology, clinical refers to, when ...
Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modifi...
Background: Atherosclerosis is a chronic inflammatory disease of the large arteries and a leading ca...
Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion, however, causes ...
Adverse cardiac remodeling after myocardial infarction ultimately causes heart failure. To stimulate...
Ischemic heart disease is the leading cause of death worldwide. Occlusion of a coronary artery resul...
Myocardial infarction is the leading cause of death world-wide. It is characterized by cardiomyocyte...
Myocardial infarction (MI) affects nearly 800,000 people every year in the United States. As it stan...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Atherosclerosis is a leading cause of worldwide morbidity and mortality whose management could benef...
Immunosuppressive agents are used for the treatment of immune-mediated myocarditis; however, the nee...
Ischemic cardiac disease (ICD) is a cardiovascular disease with high morbidity and mortality. In thi...
Myocardial ischemia-reperfusion injury is a kind of pathologic physiology, clinical refers to, when ...
Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modifi...
Background: Atherosclerosis is a chronic inflammatory disease of the large arteries and a leading ca...